That was higher than the 0.3% gain during the third quarter. Target posted a 2% gain in the second quarter and a 3.7% drop in ...
Target’s profit will be pressured in the first quarter due to tariff uncertainty and bad weather, but will then see ...
The company also cut its long-term outlook at its New York City investor day, much to the frustration of analysts. Target ...
Investors have rapidly been losing faith in the stock market—one of Wall Street’s most prominent bulls just joined their ...
Scotiabank initiated coverage of Gain Therapeutics (GANX) with an Outperform rating and $12 price target Gain’s GT-02287 is potential blockbuster drug in Phase 1b that could be a disease-modifyi ...
Target plans to drive $15B in sales growth by 2030 by expanding product categories, digital marketplace, owned brands, stores ...
Target (TGT) may have to do a lot more this year ... 1.18% estimate (Last year comparable sales fell 4.4%; Walmart US reported a 4.6% gain in its fourth quarter.) ...
Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 target price on shares of Gain ...